Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.1%

327 terminated/withdrawn out of 2315 trials

Success Rate

83.6%

-2.9% vs industry average

Late-Stage Pipeline

45%

1049 trials in Phase 3/4

Results Transparency

32%

527 of 1662 completed trials have results

Key Signals

132 recruiting527 with results280 terminated47 withdrawn

Enrollment Performance

Analytics

Phase 3
686(32.6%)
Phase 2
586(27.9%)
Phase 1
388(18.4%)
Phase 4
363(17.3%)
N/A
81(3.8%)
2104Total
Phase 3(686)
Phase 2(586)
Phase 1(388)
Phase 4(363)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2315)

Showing 20 of 2315 trials
NCT06637631Phase 2Recruiting

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Role: lead

NCT07053423Phase 4Recruiting

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Role: lead

NCT06290128Phase 3Recruiting

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Role: lead

NCT07170917Phase 2Recruiting

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Role: lead

NCT07646548Phase 1Not Yet Recruiting

Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants

Role: lead

NCT07185009Phase 3Recruiting

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Role: lead

NCT07225569Phase 2Recruiting

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Role: lead

NCT07547436Phase 2Recruiting

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

Role: lead

NCT06859099Phase 3Enrolling By Invitation

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

Role: lead

NCT06714461Completed

A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia

Role: lead

NCT07643025Phase 2Not Yet Recruiting

Belumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease (cGvHD) After Steroid Failure

Role: collaborator

NCT02332850Phase 1Completed

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT06444451Phase 2Terminated

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Role: lead

NCT05922761Phase 2Recruiting

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Role: collaborator

NCT07634692Not Yet Recruiting

An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia

Role: lead

NCT05767346Phase 3Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Role: collaborator

NCT05776979Phase 2Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Role: collaborator

NCT07088068Phase 3Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Role: lead

NCT07286214Phase 4Recruiting

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

Role: lead

NCT06500702Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Role: lead